Kura Oncology reported total revenue of $22.8 million for the third quarter 2026, falling short of the $24.9 million analyst estimate despite significant commercial traction for its lead product. The company's net loss per share of $0.78 narrowed compared to the prior year and was better than the $0.83 loss anticipated by the market.
Key Highlights
- KOMZIFTI net product revenue reached $13.9 million, a 53% sequential increase driven by 150 new patient starts and a 65% rise in total prescriptions.
- Collaboration revenue decreased to $8.9 million from $20.8 million in the third quarter 2025, primarily due to the timing of performance obligations under the Kyowa Kirin agreement.
- Total liquidity was bolstered by a new strategic financing agreement with Oberland Capital for up to $300 million, extending the cash runway into 2028.
- Management reached FDA alignment on a monotherapy registrational study for darlifarnib in salivary gland cancer, with a planned initiation in the first half of 2027.